Patrick Xin has served as Senior Director of Clinical Data Management since December 2025, leading the company’s clinical data strategy and execution across global programs to support high-quality regulatory filings, scientific presentations, and publications. Prior to joining Immuneering, Patrick served as Executive Director at Arcturus Therapeutics, leading integrated biometric data management and statistical programming functions, and as Director of the Clinical Research DataCore at NYU Langone Health.
Patrick holds an M.S. in Computer Science from New Jersey Institute of Technology, an M.A. in Biochemistry from City University of New York, and a B.S. in Pharmaceutical Science from Fudan University, China
Vinny Hayreh, MD
Vinny Hayreh, MD, is a physician executive with extensive experience in oncology clinical development, medical affairs, and pharmacovigilance across global pharmaceutical and biotechnology organizations. She currently serves as Immuneering’s Vice President of Clinical Development, leading oncology programs from early clinical development through late-stage trials. She is also the Founder and CEO of Hayreh LLC, a pharmaceutical and biotechnology consulting firm providing clinical strategy, medical monitoring, and pharmacovigilant support for oncology programs. Previously, she held senior leadership roles including Senior Medical Director at Janssen Pharmaceuticals (Johnson & Johnson), Clinical Trial Lead (Medical Director) at Bristol Myers Squibb, Global Medical Affairs Leader and Global Safety Physician at AstraZeneca, and Senior Manager in Global Safety and Medical Communications at Amgen. Vinny received her medical degree from Grace University and completed post-graduate training at the University of California, Los Angeles.
Loretta Sullivan, MD, MPH
Loretta Sullivan, MD, MPH, has dedicated her life to improving global health. Over the last decade, she has held clinical leadership roles within the biopharmaceutical industry, including Genentech/Roche, Lilly, Astellas, J&J, ALX Oncology and Clovis Oncology. Prior to joining industry, Dr. Sullivan worked as an epidemiologist with the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and various non-governmental organizations in over 30 countries. Dr. Sullivan earned her undergraduate degree from Dartmouth College, her MPH in epidemiology at UCLA and her medical degree at the University of Colorado with an internal medicine residency at UCLA and hematology/oncology fellowship at Stanford. She is a veteran, having served in the U.S. Public Health Service, and she is fluent in five languages. Loretta lives in Denver, Colorado, with her husband and three sons. In her spare time, she plays USTA tennis and loves to ski.
Courtney Dugan
Courtney Dugan joined Immuneering in December 2025 as Vice President, Head of Investor Relations and Corporate Communications. She brings 18 years of experience in investor relations, financial communications, corporate positioning, and reputation management across the healthcare industry. She previously served as Vice President, Head of Investor Relations and Corporate Affairs at Y-mAbs Therapeutics from May 2023 to November 2025, following the company’s acquisition by SERB Pharmaceuticals. Earlier, Ms. Dugan led the investor relations and corporate communications functions at Olema Oncology and Pyxis Oncology. From April 2020 to November 2021, Ms. Dugan served as Senior Director of Global Finance Communications at Johnson & Johnson, where she led strategic purpose-driven initiatives aimed at enhancing the company’s corporate perception among key external audiences. Prior to Johnson & Johnson, she held leadership roles of increasing responsibility at key investor relations and financial communications agencies – including Real Chemistry, Syneos Health and ICR, Inc. – serving clients across the biotech, pharmaceutical and life sciences industries. Ms. Dugan received a B.A. in Corporate Communications and Public Affairs from Southern Methodist University and an M.B.A from Columbia Business School.
Laurie Keating, J.D.
Ms. Keating has served on our Board of Directors since March 2021. Ms. Keating previously served as the Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc., from March 2019 until September 2021, and also served as its Senior Vice President, General Counsel and Secretary from September 2014 until March 2019. From September 2004 until January 2014, she served as the Senior Vice President, General Counsel and Secretary of Millennium Pharmaceuticals, Inc., a wholly owned oncology-focused subsidiary of Takeda Pharmaceutical Company Limited since 2008, and was the founding Chief Executive Officer and a member of the board of directors of Hydra Biosciences. Since December 2021 Ms. Keating has served on and currently chairs the board of directors of a clinical-stage biopharmaceutical company, PepGen Inc. (Nasdaq: PEPG), where she also chairs the Audit Committee and is a member of the Compensation and Nominating and Corporate Governance committees. From November 2021 until the company was acquired by Merck in January 2023, she served on the board of directors of Imago BioSciences (Nasdaq: IMGO), and from 2005 until March 2022 she served on the board of directors of MassBIO, a non-profit organization. Ms. Keating earned her A.B. in economics from the University of California, Berkeley and her J.D. from the University of California, Hastings College of the Law.